Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) EBIT (2016 - 2025)

Historic EBIT for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to -$32.9 million.

  • Standard Biotools' EBIT fell 2336.79% to -$32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.4 million, marking a year-over-year decrease of 1942.57%. This contributed to the annual value of -$175.2 million for FY2024, which is 12876.76% down from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' EBIT is -$32.9 million, which was down 2336.79% from -$25.7 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' EBIT peaked at -$11.3 million during Q4 2021, and registered a low of -$73.8 million during Q4 2024.
  • For the 5-year period, Standard Biotools' EBIT averaged around -$28.6 million, with its median value being -$25.7 million (2025).
  • As far as peak fluctuations go, Standard Biotools' EBIT soared by 5475.2% in 2023, and later tumbled by 26269.51% in 2024.
  • Quarter analysis of 5 years shows Standard Biotools' EBIT stood at -$11.3 million in 2021, then crashed by 87.51% to -$21.1 million in 2022, then fell by 1.3% to -$21.4 million in 2023, then crashed by 245.24% to -$73.8 million in 2024, then soared by 55.39% to -$32.9 million in 2025.
  • Its EBIT was -$32.9 million in Q3 2025, compared to -$25.7 million in Q2 2025 and -$33.0 million in Q1 2025.